Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
You’d sort of assume that as 1801 isn’t dabbling with any genetic engineering, cloning, human embryos, and TYK2/JAK1 is effectively existing technology, there shouldn’t be any red flags to an ethics committee?
Nice post, SOG.
Now this might be a bit random, as I’m not a pharma person, but it seems to me that a comment someone once made to me, that the pharma industry is very incestuous, seems to apply here…. Let me explain:
We’ve got Udai Banerai and Michelle Garrett well plugged into the CRUK/CPF development programmes, but AZ5363 (a preclinical asset) into the mix as well.
https://pubmed.ncbi.nlm.nih.gov/29066505/
Now, Sierra (licensed?) another Astra product, AZD5153 and if I remember correctly, were planning combo trials with AZD5153 and SRA737? I remember (vagueley) the pipeline page on Sierra’s web site but of course that’s lost now that they are part of GSK. I my have to have a play with the way back machine at the weekend to confirm this.
Just strikes me as a bit weird that some new dude arrives on these boards a couple of days ago, mentioning AZ when there’s all this ancient and recent history, like a little love triangle with CRUK, Sierra and Astra linked by the above people. Plus GSK stirring it up by acquiring Sierra whilst Tim (and John?) are ex-GSK guys.
Told you it was going to be random, didn’t I?
:)
Anyone care to add more links or branches to this pharma family tree? For example, nobody has mentioned Tripana Sen for ages. But I’m sure there are other key people as well?
All the best,
SCH.
SOG - it’s really a very simple reason why departments like MHRA aren’t performing - they’ve been stripped of funding and resources.
Here’s a comparison - the Marine Accidents Investigation Branch used to get full reports done in about 6 months. Now they are taking up to three and a half years, even for fatal accidents. They’re firefighting and issuing interim reports to cover the basic legal aspects and support court cases, but the full reports are stuck and I wonder if they will ever be completed.
Have a look at the dates on these…. it’s shocking:
https://www.gov.uk/government/publications/marine-accident-investigation-branch-current-investigations/marine-accident-investigation-branch-current-investigations
RSI=79 !
https://youtu.be/kUsFWO08CO0
There are many articles that agree with you, Seawolf!
This is just one….
https://ascopubs.org/doi/10.1200/JCO.2019.37.15_suppl.3095
:)
2pm update:
Crossed the 90trades that I look for as a sign of decent volume
Trades 93
Vol Sold 115,648
Vol Bought 115,473
But the bought and sold are clearly wrong - there are pairs of 20k trades recorded as sells which are obviously B&ISA transactions, so for every instance of that it’s 40k of sells incorrectly recorded. There’s certainly one, maybe more, of there today.
- who invited Parker to the JP Morgan event? Would be interesting g to know.
Anyway, they bid up from $110 to $200 a share. Raising the deal value to $10.8 Bn.
That’s one massive deal!
“Chk1 Is still the one that will be interesting who gets.....will it be a few pharmaceuticals for different indications or the whole cake?”
I’d forgotten about that strategy. When I last suggested that 737 could be licensed to multiple companies for different combos, the suggestion eas dismissed as “too complex”.
Regardless of whether it’s too complex or not to do a multiple licensing deal, this could be a bargaining chip - if you want “exclusive” then it’s going to cost.
All depends on how CPF want to play it. Maybe their raison d’etre is to license it as widely as possible?